Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.

• Status: Recruiting
• Trial end date: 2024-12-20
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety of Fosaprepitant Dimeglumine Injection for the prevention of nausea and vomiting caused by tumor chemotherapy drugs, analyze the characteristics of the applicable population and clinical medication of Fosaprepitant Dimeglumine, evaluate the risk factors that may affect the efficacy of drug use, and compare the clinical benefits of different drug use modes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xijing Hospital
• Treatments: Aprepitant; Fosaprepitant

Criteria

Inclusion Criteria:

• Patients with nausea and vomiting caused by chemotherapy

• Patients who volunteered to participate in the study

Exclusion Criteria:

• Hypersensitive to any component in this product

• Patients taking pimozide, terfenadine, astemizole and cisapride